世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

てんかん治療薬の市場規模、シェア、動向分析レポート:製品別(第一世代抗てんかん薬、第二世代抗てんかん薬、第三世代抗てんかん薬)、地域別、セグメント別予測、2023年~2030年


Epilepsy Drugs Market Size, Share & Trends Analysis Report By Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Region, And Segment Forecasts, 2023 - 2030

てんかん治療薬市場の成長と動向 Grand View Research, Inc.の最新レポートによると、てんかん治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率5.1%を記録し、2030年には153.5億米ドルに達する... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月4日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
91 英語

1~3営業日


 

サマリー

てんかん治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、てんかん治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率5.1%を記録し、2030年には153.5億米ドルに達すると予測されています。てんかん発作の治療に有効な新薬の開発に対する政府資金の増加は、てんかん治療薬市場の成長にとってインパクトの大きいレンダリングドライバーである。米国てんかん協会(AES)は、米国神経学会、てんかん財団、グラス財団などの他の組織と連携して、研究開発活動に資金を提供し、さまざまなプログラムを通じて医師に治療ラインの認識トレーニングを提供しています。

さらに、Epilepsy Foundation、American Epilepsy Society、Epilepsy Association of Central Florida、CURE Epilepsy、Anita Kaufmann Foundationなどの団体が実施する様々な啓発プログラムは、診断率と治療率をさらに加速させています。このことは、予測期間中の市場成長を促進すると予想される。

てんかん治療薬市場レポートハイライト

- 第二世代の抗てんかん薬は、第二の急成長セグメントとなる見込み。このセグメントには、Lamotrigine(Lamictal)、Levetiracetam(Keppra)、Brivaracetam(Briviact)、Perampanel(Fycompa)などが含まれる。

- 第3世代の抗てんかん薬セグメントは、2022年に約39.3%という最大の売上シェアを占めた。同分野の成長の主な要因としては、作用機序が改善され副作用の少ない有効性の高い薬剤の上市や、新たなパイプライン薬剤の上市待ちなどが挙げられる。

- 2022年の売上高シェアは、北米が約45%と最も高く、市場を支配している。同地域ではてんかんの有病率が高く、罹患者数が多いことが、てんかん治療薬市場の主な牽引要因となっている。

- アジア太平洋地域は、予測期間においてCAGR 6.3%と最も高い成長率で拡大すると推定される。てんかんに関するセクター間世界行動計画、てんかんに対する世界キャンペーンなどの政府主導の取り組みや、新世代の抗てんかん薬の発売が、同地域における同市場の成長を促進する原動力となっています。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Penetration & Growth Prospect Mapping
3.5. Global Epilepsy Drug Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis
4.1. Epilepsy Drug Market: Key Takeaways
4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
4.3. First Generation Anti-epileptics
4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Second Generation Anti-epileptics
4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Third Generation Anti-epileptics
4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug
5.1. Regional Outlook
5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
5.3. North America
5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.6. Sweden
5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.7. Norway
5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. Saudi Arabia
5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.2. South Africa
5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. UCB S.A., Belgium
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Product Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Sanofi
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Product Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Pfizer, Inc.
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Product Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Otsuka America Pharmaceutical, Inc.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Product Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Eisai Co., Ltd.
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Product Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Novartis AG
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Product Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Abbott Laboratories, Inc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Product Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Sanofi Aventis S.A.
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Product Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. GlaxoSmithKline plc
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Product Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Sunovion Pharmaceuticals, Inc.
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Product Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Jazz Pharmaceuticals plc
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Product Benchmarking
6.2.11.4. Strategic Initiatives
6.2.12. Neurelis, Inc.
6.2.12.1. Company Overview
6.2.12.2. Financial Performance
6.2.12.3. Product Benchmarking
6.2.12.4. Strategic Initiatives

 

ページTOPに戻る


 

Summary

Epilepsy Drugs Market Growth & Trends

The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights

• Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).

• The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.

• North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.

• Asia Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Penetration & Growth Prospect Mapping
3.5. Global Epilepsy Drug Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis
4.1. Epilepsy Drug Market: Key Takeaways
4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
4.3. First Generation Anti-epileptics
4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Second Generation Anti-epileptics
4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Third Generation Anti-epileptics
4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug
5.1. Regional Outlook
5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
5.3. North America
5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.6. Sweden
5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.7. Norway
5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. Saudi Arabia
5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.2. South Africa
5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. UCB S.A., Belgium
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Product Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Sanofi
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Product Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Pfizer, Inc.
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Product Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Otsuka America Pharmaceutical, Inc.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Product Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Eisai Co., Ltd.
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Product Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Novartis AG
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Product Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Abbott Laboratories, Inc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Product Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Sanofi Aventis S.A.
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Product Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. GlaxoSmithKline plc
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Product Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Sunovion Pharmaceuticals, Inc.
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Product Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Jazz Pharmaceuticals plc
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Product Benchmarking
6.2.11.4. Strategic Initiatives
6.2.12. Neurelis, Inc.
6.2.12.1. Company Overview
6.2.12.2. Financial Performance
6.2.12.3. Product Benchmarking
6.2.12.4. Strategic Initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

Grand View Research社の医療機器分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る